Patents Assigned to AstraZeneca
  • Novel 8-Sulfonylamino-3 Aminosubstituted Chroman or Tetrahydronaphtalene Derivatives Modulating the 5Ht6 Receptor
    Publication number: 20090030038
    Abstract: The present invention relates to new compounds of formula I. (I) wherein R1 to R12, X, Q and n are as defined as in formula I, or salts, solvates or solvated salts thereof, processes for their preparation and to new intermediates used in the preparation thereof, pharmaceutical formulations containing said compounds and to the use of said compounds in therapy.
    Type: Application
    Filed: May 22, 2006
    Publication date: January 29, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Chester Chu, Andrew Lister, Gunnar Nordvall, Carl Petersson, Didier Rotticci, Daniel Sohn, Stefan Von Berg
  • Piperidine derivatives useful as modulators of chemokine receptor activity
    Patent number: 7482363
    Abstract: The present invention provides a compound of formula (I), wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.
    Type: Grant
    Filed: March 17, 2003
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Hitesh Sanganee, Brian Springthorpe
  • Non-amide nonanes
    Patent number: 7482338
    Abstract: Compounds of Formula I: and pharmaceutically-acceptable salts thereof, wherein Q, E and D are as defined in the specification, enantiomers, in vivo-hydrolysable precursors, pharmaceutical compositions and formulations containing them, methods of using them to treat diseases and conditions either alone or in combination with other therapeutically-active compounds or substances, processes and intermediates used to prepare them and uses of them for diagnostic and analytic purposes.
    Type: Grant
    Filed: September 24, 2004
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Glen Ernst, Eifion Phillips, Richard J Schmiesing
  • Pyrimidine derivatives as modulators of chemokine receptor activity
    Patent number: 7482355
    Abstract: Compounds of formula (1), pharmaceutically acceptable salts, solvates and in vivo hydrolysable esters thereof, have activity as pharmaceuticals, in particular as modulators of chemokine receptor (especially CXCR2) activity, and may be in the treatment (therapeutic or prophylactic) of conditions/diseases in human and non-human animals which are exacerbated or caused by excessive or unregulated production of chemokines.
    Type: Grant
    Filed: August 20, 2003
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Mark Richard Ebden, Premji Meghani, Anthony Ronald Cook, John Steele, Lal Lashkar Singh Cheema
  • Antibodies directed to monocyte chemo-attractant protein-1 (MCP-1) and uses thereof
    Patent number: 7482434
    Abstract: Embodiments of the invention described herein relate to antibodies directed to the antigen monocyte chemo-attractant protein-1 (MCP-1) and uses of such antibodies. In particular, in accordance with some embodiments, there are provided fully human monoclonal antibodies directed to the antigen MCP-1. Nucelotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDRs), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: December 19, 2006
    Date of Patent: January 27, 2009
    Assignee: AstraZeneca AB
    Inventors: Jean M. Gudas, Mary Haak-Frendscho, Orit Foord, Meina L. Liang, Kiran Ahluwalia, Sunil Bhakta
  • 1,2,3,4-Tetrahydroisoquinoline Derivatives, Preparations Thereof and Uses Thereof
    Publication number: 20090023728
    Abstract: Compounds of general formula (I) wherein D, E, R1, R2, R3, R4, R5, R6 and R7 are as defined in the specification, as well as salts, enantiomers thereof and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: December 20, 2004
    Publication date: January 22, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Justin Ripper, Ian Jenkins, Phuc Van Le, Ron Quinn, Christian Janssen
  • Piperazines and Piperidines as Mglur5 Potentiators
    Publication number: 20090023711
    Abstract: Compounds of Formula I or pharmaceutically acceptable salts or solvates thereof: wherein Ar1, Ar2, A, X, Y, m, n and R1, R2, R3, R4 and R5 are as described in the specification, processes for their preparation, pharmaceutical formulations comprising them and their use in therapy, particularly in the therapy of neurological and psychiatric disorders associated with glutamate dysfunction.
    Type: Application
    Filed: January 5, 2007
    Publication date: January 22, 2009
    Applicant: AstraZeneca AB
    Inventors: Abdelmalik Slassi, Methvin Isaac, Jalaj Arora, Dean Brown
  • Substituted 2-Aminopyrimidine-4-Ones, Their Pharmaceutical Compositions And Their Use In The Treatment And/Or Prevention Of Ab-Related Pathologies
    Publication number: 20090023762
    Abstract: This invention relates to novel compounds having the structural formula (I) below: and to their pharmaceutically acceptable salt, compositions and methods of use. These novel en compounds provide a treatment or prophylaxis of cognitive impairment, Alzheimer Disease, neurodegeneration and dementia.
    Type: Application
    Filed: December 18, 2006
    Publication date: January 22, 2009
    Applicants: ASTRAZENECA AB, ASTEX THERAPEUTICS LIMITED
    Inventors: Stefan Berg, Jeremy Burrows, Sven Hellberg, Katharina Hogdin, Karin Kolmodin
  • Novel Compounds 737
    Publication number: 20090023704
    Abstract: The present invention relates to novel xanthine compounds of the general formula (I) wherein R1, R2, R3 and R4 are as defined, having a positive allosteric GABAB receptor (GBR) modulator effect, methods for the preparation of said compounds and to their use, optionally in combination with a GABAB agonist, for the inhibition of transient lower esophageal sphincter relaxations, for the treatment of gastroesophageal reflux disease, as well as for the treatment of functional gastrointestinal disorders and irritable bowel syndrome (IBS).
    Type: Application
    Filed: April 17, 2008
    Publication date: January 22, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Leifeng Cheng, Sara Holmqvist, Florian Raubacher, Peter Schell
  • COMPOUNDS AND THEIR USES 707
    Publication number: 20090023746
    Abstract: The present invention relates to isoquinolinone derivatives of formula (I): wherein R1, R2, R3, R4, R5, R6 and R7 are as herein defined; processes for their preparation, pharmaceutical compositions containing them and their use in therapy.
    Type: Application
    Filed: April 4, 2008
    Publication date: January 22, 2009
    Applicant: AstraZeneca AB
    Inventors: Matthew Hallam, Barrie Martin, Piotr Raubo, Bryan Roberts, Stephen St-Gallay, Paul Willis
  • PYRIMIDINE DERIVATIVES 934
    Publication number: 20090023719
    Abstract: A compound of formula (I) where one of A1, A2 or A3 is N, and the others are independently selected from CH or N; ring B is a fused 5 or 6-membered carbocyclic or heterocyclic which is optionally substituted as defined in the specification, and R1, R2, R3, R4, and n are as defined in the specification. The compounds are inhibitors of EphB4 or EphA2 and therefore may be useful in pharmaceutical compositions for the treatment of conditions such as cancer.
    Type: Application
    Filed: July 16, 2008
    Publication date: January 22, 2009
    Applicant: Astrazeneca AB
    Inventors: Bernard Christophe Barlaam, Richard Ducray, Jason Grant Kettle
  • Citrate Salt of an Indole Derivative and its Pharmaceutical Use
    Publication number: 20090023732
    Abstract: The salt, the 2-hydroxy-3-[5-(morpholin-4-ylmethyl)pyridin-2-yl]1H-indole-5-carbonitrile citrate, a process for its preparation, pharmaceutical formulations containing it and the use of it in therapy, and particularly in the therapy of GSK3 related conditions and disorders.
    Type: Application
    Filed: January 31, 2007
    Publication date: January 22, 2009
    Applicant: AstraZeneca AB
    Inventors: Anna-Lena Berg, Ratan Bhat, Tesfai Sebhatu, Erica Stahle
  • Compounds - 945
    Publication number: 20090018134
    Abstract: A compound of formula (I) or a pharamaceutically acceptable salt thereof, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, for example in the treatment of proliferative disease such as cancer and particularly in disease mediated by an mTOR kinase and/or one or more PI3K enzyme.
    Type: Application
    Filed: July 9, 2008
    Publication date: January 15, 2009
    Applicant: AstraZeneca AB
    Inventors: Kurt Gordon PIKE, Jeffrey James Morris
  • New Pyridine Analogues X 161
    Publication number: 20090018166
    Abstract: The present invention relates to certain new pyridin analogues of Formula (I) to processes for preparing such compounds, to their utility as P2Y12 inhibitors and as anti-trombotic agents etc, their use as medicaments in cardiovascular diseases as well as pharmaceutical compositions containing them.
    Type: Application
    Filed: January 11, 2008
    Publication date: January 15, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Kosrat Amin, Thomas Antonsson, Christoffer Bengtsson, David Brown, Ruth Bylund, Daniel Hovdal, Fabrizio Giordanetto, Johan Johansson
  • Therapeutic Compounds
    Publication number: 20090018116
    Abstract: Compounds of formula I or pharmaceutically acceptable salts thereof: wherein R1, R2, R3, R4 and n are as defined in the specification as well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain.
    Type: Application
    Filed: May 20, 2005
    Publication date: January 15, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Shujuan Jin, Ziping Liu, Claire Milburn, Miroslaw Tomaszewski, Christopher Walpole, Zhong-Yong Wei, Hua Yang
  • Compounds and Uses Thereof
    Publication number: 20090018112
    Abstract: This invention relates to novel compounds having the structural formula I below: and their pharmaceutically acceptable salts, tautomers or in vivo-hydrolysable precursors, compositions and methods of use thereof. These novel compounds provide a treatment or prophylaxis of anxiety disorders, cognitive disorders, and/or mood disorders.
    Type: Application
    Filed: August 27, 2008
    Publication date: January 15, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Marc J. Chapdelaine, Cyrus J. Ohnmacht, Christopher Becker, Hui-Fang Chang, Bruce T. Dembofsky
  • Compounds for the treatment of neurological, psychiatric or pain disorders
    Patent number: 7476684
    Abstract: The present invention is directed to novel compounds, their use in therapy and pharmaceutical compositions comprising said novel compounds.
    Type: Grant
    Filed: September 20, 2006
    Date of Patent: January 13, 2009
    Assignee: AstraZeneca AB
    Inventors: Alexander Minidis, David Wensbo, Methvin Isaac, Abdelmalik Slassi, Jalaj Arora, Tao Xin, Louise Edwards, Caroline Eriksson, Veronica Profir, Per-Olov Bergstrom
  • Substituted thieno- and thiazolo- [2,3-d]pyrimidines and [2,3-c]pyridines as inhibitors of Tie2
    Patent number: 7476677
    Abstract: A compound of the formula(I); wherein the substituents are as defined in the text for use in the production of an anti-angiogenic effect in a warm blooded animal such as man. The compounds are inhibitors Tie2 receptor tyrosine kinase (TEK).
    Type: Grant
    Filed: February 1, 2005
    Date of Patent: January 13, 2009
    Assignee: AstraZeneca AB
    Inventors: Clifford David Jones, Richard William Arthur Luke, William McCoull
  • Thiophene-2-Carboxamide Derivatives as Alpha 7 Nicotinic Receptor Modulators
    Publication number: 20090012127
    Abstract: Compounds of Formula (I) wherein E, A and R1 are as described in the specification, pharmaceutically-acceptable salts, methods of making, pharmaceutical compositions containing and methods for using the same.
    Type: Application
    Filed: June 26, 2006
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Thomas R. Simpson, Michael Balestra, Dean G. Brown, Cathy L. Dantzman, Glen E. Ernst, William Frietze, Christopher R. Holmquist, James Kang, Frances M. McLaren, Reed W. Smith, JR., James M. Woods
  • New Aza-Bicyclohexane Compounds Useful As Inhibitors Of Thrombin
    Publication number: 20090012087
    Abstract: This invention relates to novel pharmaceutically useful compounds of formula (I), in particular compounds that are competitive inhibitors of trypsin-like serine proteases, especially thrombin, their use as medicaments, pharmaceutical compositions containing them and synthetic routes to their production.
    Type: Application
    Filed: July 2, 2008
    Publication date: January 8, 2009
    Applicant: ASTRAZENECA AB
    Inventors: Jonas Branalt, Ingemar Nilsson, Magnus Polla